Redeye: Xvivo Perfusion - Strong Growth Ahead

Xvivo Perfusion delivered a strong quarter for sales related to warm perfusion (excluding durable goods). After an analysis of the report and information from the earnings call, we lower our expectations for growth in the near-term, however, resulting in a lowered fair value.

Read more and download the research update: http://bit.ly/2SCHHS0

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/